CHESHIRE, Conn.--(BUSINESS WIRE)--Soliris® (eculizumab), a first-in-class terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), reversed thrombocytopenia (abnormally low platelet count) in a significant proportion of patients with both paroxysmal nocturnal hemoglobinuria (PNH) and pre-existing thrombocytopenia, according to an analysis of data from 49 patients enrolled in clinical trials of Soliris in PNH. Soliris increased platelet count by inhibiting terminal complement-mediated platelet activation and consumption, potentially reducing the risk of developing thrombosis. Improvement in platelet count was observed in thrombocytopenic PNH patients irrespective of history of thrombosis or bone marrow failure.
